Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Upper respiratory tract infection? 1,339 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 1,339 reports of Upper respiratory tract infection have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.9% of all adverse event reports for SECUKINUMAB.

1,339
Reports of Upper respiratory tract infection with SECUKINUMAB
0.9%
of all SECUKINUMAB reports
196
Deaths
315
Hospitalizations

How Dangerous Is Upper respiratory tract infection From SECUKINUMAB?

Of the 1,339 reports, 196 (14.6%) resulted in death, 315 (23.5%) required hospitalization, and 200 (14.9%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for SECUKINUMAB.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) LENALIDOMIDE (1,334)

Which SECUKINUMAB Alternatives Have Lower Upper respiratory tract infection Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection SECUKINUMAB Demographics